Dividend Contenders List: Top 15

12. Merck & Co., Inc. (NYSE:MRK)

Dividend Yield as of March 12: 3.47%

Merck & Co., Inc. (NYSE:MRK) is an American multinational pharmaceutical company. It maintains a competitive edge in the market, supported by a pipeline of approximately 20 potential growth drivers with blockbuster potential. Its late-stage developments in infectious diseases, oncology, and cardiometabolic treatments further enhance its long-term prospects. With strong commercial execution, a diversified portfolio, and a commitment to innovation, the company remains well-positioned to navigate short-term challenges while maintaining a solid growth trajectory.

In the fourth quarter of 2024, Merck & Co., Inc. (NYSE:MRK) reported strong financial performance, with revenue rising 7% year-over-year to $15.6 billion. The company has strengthened its presence in specialty pharmaceuticals and oncology, with Keytruda continuing to play a key role in cancer treatment while driving substantial revenue growth. Its strong market standing has enabled Merck to generate healthy cash flow, reinforcing its focus on shareholder returns. In fiscal 2024, Keytruda sales increased by 18% compared to the previous year, reaching $29.5 billion.

On January 28, Merck & Co., Inc. (NYSE:MRK) declared a quarterly dividend of $0.81 per share, which was in line with its previous dividend. Overall, the company has been growing its payouts for 14 consecutive years. As of March 12, the stock has a dividend yield of 3.47%.